TLSI TriSalus Life Sciences, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1826667 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY33.7%
TTM EPS YoY80.7%
Revenue 3-yr CAGR42.5%
Net income 3-yr CAGR—
Margins
Gross margin86.5%
Operating margin-63.0%
Net margin-56.6%
FCF margin-53.3%
EBITDA margin-61.8%
Returns
ROE—
ROA-55.8%
ROIC (approx.)—
Asset turnover0.99x
Leverage & solvency
Liabilities / assets98.8%
Debt / equity47.60x
Current ratio4.22x
Interest coverage-4.92x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.88M | $11.41M | $8.90M | $13.21M | $11.57M | $11.21M | $9.17M | $8.26M |
| Cost of revenue | $1.78M | $1.51M | $1.23M | $1.76M | $1.91M | $1.80M | $1.50M | $1.22M |
| Gross profit | $11.10M | $9.90M | $7.67M | $11.44M | $9.66M | $9.41M | $7.67M | $7.04M |
| R&D expense | $3.19M | $3.14M | $3.22M | $2.57M | $5.70M | $3.67M | $3.02M | $2.96M |
| SG&A expense | $4.88M | $5.16M | $5.45M | $4.17M | $6.13M | $5.91M | $5.25M | $4.66M |
| Operating income | -$7.71M | -$9.81M | -$8.41M | -$3.27M | -$9.01M | -$7.33M | -$7.33M | -$7.58M |
| Interest expense | $1.56M | $1.49M | $1.44M | $1.45M | $1.46M | $1.42M | $1.21M | $1.07M |
| Pretax income | -$8.85M | -$9.18M | $1.54M | -$9.75M | -$10.81M | -$8.29M | -$10.37M | -$10.11M |
| Income tax | $4,000 | $4,000 | $4,000 | $0 | $5,000 | -$3,000 | $5,000 | -$1,000 |
| Net income | -$8.85M | -$9.19M | $1.54M | -$9.75M | -$10.81M | -$8.29M | -$10.38M | -$10.11M |
| EBITDA | -$7.58M | -$9.68M | -$8.28M | -$3.15M | -$8.85M | -$7.17M | -$7.16M | -$7.39M |
| EPS (basic) | -0.15 | -0.16 | 0.03 | — | -0.96 | -0.27 | -0.39 | — |
| EPS (diluted) | -0.15 | -0.16 | 0.03 | — | -0.96 | -0.27 | -0.39 | — |
| Weighted avg. shares (diluted) | 58.47M | 58.30M | 52.31M | — | 43.06M | 32.90M | 28.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.06M | $46.29M | $56.55M | $20.44M | $23.04M | $26.84M | $13.35M | $8.88M |
| Receivables | $6.13M | $6.46M | $5.21M | $6.56M | $5.00M | $5.57M | $5.45M | $5.09M |
| Inventory | $4.64M | $4.21M | $3.78M | $3.08M | $3.28M | $3.81M | $4.16M | $4.05M |
| Current assets | $54.90M | $59.74M | $68.14M | $32.24M | $33.33M | $38.08M | $25.10M | $20.67M |
| PP&E, net | $1.83M | $1.84M | $1.94M | $1.81M | $1.83M | $1.71M | $1.97M | $1.67M |
| Total assets | $57.56M | $62.45M | $70.98M | $35.33M | $36.46M | $41.32M | $28.62M | $23.97M |
| Current liabilities | $13.01M | $11.17M | $11.79M | $11.50M | $10.91M | $9.32M | $11.75M | $10.23M |
| Long-term debt | $32.37M | $33.06M | $33.08M | $33.05M | $32.76M | $32.27M | $31.70M | $22.08M |
| Total debt | $32.37M | $33.06M | $33.08M | $33.05M | $32.76M | $32.27M | $31.70M | $22.08M |
| Total liabilities | $56.88M | $55.90M | $58.17M | $69.19M | $63.19M | $60.74M | $62.99M | $49.87M |
| Shareholders' equity | $680,000 | $6.55M | $12.81M | -$33.86M | -$26.73M | -$19.42M | -$34.37M | -$25.89M |
| Net debt | -$8.69M | -$13.22M | -$23.47M | $12.61M | $9.73M | $5.43M | $18.35M | $13.21M |
| Shares outstanding | 61.66M | 61.47M | 61.41M | 50.00M | 49.89M | 37.98M | 32.27M | 31.28M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.28M | -$10.13M | -$6.48M | -$2.48M | -$3.71M | -$7.32M | -$4.50M | -$5.71M |
| Capital expenditure | $90,000 | $82,000 | $141,000 | $41,000 | $216,000 | -$93,000 | $754,000 | $50,000 |
| Free cash flow | -$5.37M | -$10.21M | -$6.62M | -$2.52M | -$3.92M | -$7.23M | -$5.25M | -$5.76M |
| Investing cash flow | -$90,000 | -$82,000 | -$141,000 | -$41,000 | -$176,000 | $93,000 | -$714,000 | -$50,000 |
| Financing cash flow | $134,000 | -$54,000 | $42.38M | $277,000 | $82,000 | $20.72M | $9.69M | $2.99M |
| Depreciation & amortization | $129,000 | $136,000 | $135,000 | $126,000 | $163,000 | $165,000 | $172,000 | $193,000 |
| Stock-based compensation | $2.83M | $2.62M | $2.47M | $2.20M | $3.42M | $1.89M | $1.62M | $1.70M |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.